Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 7/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 7/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612278 | 0.91 | MAPKAPK2 (0.53) | MAP4K4MAPKAPK2PRKD1PRKD2PRKD3 | |
| SCHEMBL3619357 | 0.90 | CCNC (0.48) | MAPKAPK2PRKD1PRKD2PRKD3CCNC | |
| SCHEMBL3614895 | 0.87 | IKBKB (0.41) | MAPKAPK2PRKD1PRKD2PRKD3IKBKB | |
| SCHEMBL3616693 | 0.86 | MAPKAPK2 (0.62) | MAPKAPK2PRKD1PRKD2PRKD3ADRB1 | |
| SCHEMBL3620099 | 0.86 | IKBKB (0.44) | MAPKAPK2PRKD1PRKD2PRKD3ACVR1 | |
| SCHEMBL3611086 | 0.85 | MAPKAPK2 (0.45) | MAPKAPK2PRKD1PRKD2PRKD3CCNC | |
| SCHEMBL3609047 | 0.85 | PRKD1 (0.50) | MAP4K4PRKD1PRKD2PRKD3ADRB1 | |
| SCHEMBL3613032 | 0.84 | PRKD1 (0.52) | MAP4K4PRKD1PRKD2PRKD3ADRB1 | |
| SCHEMBL3621763 | 0.83 | PRKD1 (0.46) | MAP4K4MAPKAPK2PRKD1PRKD2PRKD3 | |
| SCHEMBL3615592 | 0.83 | PRKD1 (0.46) | MAPKAPK2PRKD1PRKD2PRKD3CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | claimed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | MAP4K4 3364/4885MAPKAPK2 4395/4885PRKD1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.